GlaxoSmithKline CFO Interviewed on Q2 Results

LONDON, July 24, 2013 /PRNewswire/ --

Simon Dingemans, CFO, outlines the UK pharma group's Q2 performance, positive R&D pipeline news, as well as outlook and guidance for the rest of the year. 

Dingemans also gives an update on his financial strategy plan, saying, "you could see in the second quarter the benefits of the restructuring programmes and some of the financial efficiencies we've identified really contributing to drive that leverage through the P&L and accelerate earnings per share of 4% faster than the sales growth of two per cent."

The video interviews and transcripts are available now on http://video.merchantcantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-(0)207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.